First-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, normalizing sirtuin 1 levels and improving cognition in an Alzheimer's disease mouse model

Novel SIRT1 Inhibitor, showing potent effect on prostate cancer cell line

Novel SIRT1 inhibitor, inducing apoptosis in HCT116 human colon carcinoma cells partially by activating p53

Potent and selective inhibitor of SIRT2

Novel selective SIRT3 inhibitor, exhibiting SIRT3 inhibitory selectivity with IC50 value of 7.2 µM over SIRT1 (32.6 µM) and SIRT2 (33.5 µM), showing potent inhibitory activity against a group of MLLr leukemic cell lines

Novel in situ tetrazine ligation reactive silicon-rhodamine dye

Potent broad spectrm fluoroquinolone antibiotic

Fluoroquinolone antibiotic, acting as antibacterial, antineoplastic, anti-Infective agents, Inhibiting DNA-gyrase and topoisomerase

Novel inhibitor of lipopolysaccharide (LPS)-induced tumor necrosis factor (TNF)-α and interleukin (IL)-6 on microglia, exhibiting anti-inflammatory activity through ER-stress-mediated autophagy, significantly inducing the conversion ratio of LC3 II/I and

Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interactionm being cell permeable and having improved activity in the TR-FRET assay (IC50 0.13 µM)

Unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1), also inhibiting HIV-2

Novel inhibitor of MAGE-A11 with robust activity in TR-FRET for disrupting MAGE-A11:PCF11 interaction (IC50 0.40 μM)

Novel Inhibitor of the Disordered Protein, p27(Kip1)

Novel selective MDMX antagonist

Novel BRAF-targeting PROTAC, inducing efficient and potent degradation of mutant BRAF but sparing BRAFWT, inhibiting cell growth in mutant-BRAF driven cancer cells

Novel selective EGFR degrader

Novel potent EGFR degrader, being capable of penetrating the cell membrane, also degrading an exon-20 insertion mutant form of EGFR (ASV duplication)

Novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity

Novel inhibitor of HIV-1 infection by blocking viral DNA nuclear entry

Highly potent and efficacious proteolysis targeting chimera (PROTAC) degrader of PARP1 for treating cancers, potently inhibiting the growth of cancer cells bearing BRCA1/2 mutations and inducing potent and specific degradation of PARP1 in various human ca

Inhibitor of Aβ self-aggregation

Dopamine D1 receptor agonist